BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang Y, Zhong X, Zhou L, Lu J, Jiang B, Liu C, Guo J. Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review. Front Oncol 2020;10:1466. [PMID: 33042793 DOI: 10.3389/fonc.2020.01466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Z, Yin T, Qin T, Pan S, Wang M, Zhang H, Qin R. Comparison of laparoscopic versus open pancreaticoduodenectomy in patients with resectable pancreatic ductal adenocarcinoma: A propensity score-matching analysis of long-term survival. Pancreatology 2021:S1424-3903(21)00652-9. [PMID: 34969601 DOI: 10.1016/j.pan.2021.12.005] [Reference Citation Analysis]
2 Grapa CM, Mocan L, Crisan D, Florea M, Mocan T. Biomarkers in Pancreatic Cancer as Analytic Targets for Nanomediated Imaging and Therapy. Materials (Basel) 2021;14:3083. [PMID: 34199998 DOI: 10.3390/ma14113083] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Janiaud P, Agarwal A, Tzoulaki I, Theodoratou E, Tsilidis KK, Evangelou E, Ioannidis JPA. Validity of observational evidence on putative risk and protective factors: appraisal of 3744 meta-analyses on 57 topics. BMC Med 2021;19:157. [PMID: 34225716 DOI: 10.1186/s12916-021-02020-6] [Reference Citation Analysis]
4 Sturm N, Ettrich TJ, Perkhofer L. The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy. Cancers (Basel) 2022;14:217. [PMID: 35008381 DOI: 10.3390/cancers14010217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wang C, Chen H, Deng X, Xu W, Shen B. Real‐world implications of nonbiological factors with staging, clinical management, and prognostic prediction in pancreatic ductal adenocarcinoma. Cancer Medicine. [DOI: 10.1002/cam4.4910] [Reference Citation Analysis]